Abstract Library

#3926 Epidemiology and outcomes of NET in a Portuguese cancer center

Introduction: NET make up 0.5% of all cancer diagnosis in Europe. They range from indolent to highly aggressive tumors and may cause a wide range of functional symptoms. Phase III trials are difficult because of poor accrual in a heterogenous group of rare tumors.

Conference:

Presenting Author: Magno S

Authors: Magno S, Esteves S, Leite V, Claro I, Pereira D,

Keywords: neuroendocrine, epidemiology, portugal, outcomes,

#3460 Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia

Introduction: Clinical trial data show prolonged progression-free survival (PFS) with LAN in metastatic enteropancreatic NET; real-world data may demonstrate effectiveness in routine care.

Conference:

Presenting Author: Alonso T

Authors: Alonso-Gordoa T, Capdevila J, González E, Teulé A, Anido U,

Keywords: net, pancreas, lanreotide, clinical practice,

#1229 Preliminary Results on the Diagnosis of NETs in Portugal – The Cross Sectional TNE-ETC Survey

Introduction: NETs are increasing worldwide. Epidemiological data is lacking in Portugal. The NETs Study Group of the Portuguese Endocrine Society is committed to develop a National Registry.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Santos A

Authors: Santos A, Bugalho M, Lopes J, Claro I, Sanches A,

Keywords: Portugal NET,

#469 Cost-Effectiveness of Sunitinib in Patients with Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal

Introduction: Sunitinib is an oral multitargeted tyrosine kinase inhibitor approved in Europe in 2010 for use in well-differentiated pancreatic neuroendocrine tumors (pNET) that have spread or cannot be removed by surgery.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Soares M, Inês M, Contente M,

Keywords: Sunitinib, pancreatic neuroendocrine tumors, cost-effectiveness, Portugal,